[Role of mitogen-activated protein kinase in the inhibition of myocardial hypertrophy by nitric oxide in renovascular hypertensive rats]

Sheng Li Xue Bao. 2001 Feb;53(1):32-6.
[Article in Chinese]

Abstract

The aim of this study was to examine the effects of L-arginine, a nitric oxide (NO) precursor, on protein expression of endothelial nitric oxide (eNOS), nitrite/nitrate content, protein expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) and the activity of mitogen-activated protein kinase (MAPK) in cardiac tissues in renovascular hypertensive rats (RHR). The Goldblatt renovascular hypertensive model was established by two-kidney one clip method. The rats were divided into four groups, respectively treated with 50, 150 and 450 mg/kg L-arginine and 150 mg/kg L-arginine plus 10 mg/kg L-NAME (an eNOS inhibitor) (i.p.). Another group did not receive specific treatment from the 5th week after renal artery constriction. Control group was sham-operated. Mean arterial blood pressure (MABP) and the ratio of left ventricular weight to body weight (LVW/BW) were measured 8 weeks after treatment. eNOS protein expression, nitrite/nitrate content, MKP-1 protein expression and MAPK activity in cardiac tissues were detected using Western blot analysis, enzyme-reduction method and substrate in-gel kinase assay, respectively. It was found that L-arginine significantly inhibited the increase of MABP and LVW/BW, attenuated the activity of MAPK, increased protein expression of eNOS and MKP-1 and potentiated production of NO in cardiac tissue with the most effective dosage of 150 mg/kg, and these effects of L-arginine could be inhibited by L-NAME. These results suggest that MKP-1 may play an important role in the NO-induced inhibition of myocardial hypertrophy. The anti-hypertrophic effects of L-arginine may involve increase of eNOS protein expression and NO production, potentiation of MKP-1 protein expression, and inhibition of MAPK activity in the cardiac tissue of RHR.

Publication types

  • English Abstract
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Arginine / administration & dosage
  • Arginine / pharmacology*
  • Cardiomyopathy, Hypertrophic / etiology
  • Cardiomyopathy, Hypertrophic / prevention & control*
  • Cell Cycle Proteins*
  • Dual Specificity Phosphatase 1
  • Hypertension, Renovascular / complications
  • Hypertension, Renovascular / metabolism
  • Immediate-Early Proteins / biosynthesis
  • Male
  • Mitogen-Activated Protein Kinases / physiology*
  • Myocardium / metabolism
  • Nitric Oxide / pharmacology*
  • Nitric Oxide Synthase / biosynthesis
  • Phosphoprotein Phosphatases*
  • Protein Phosphatase 1
  • Protein Tyrosine Phosphatases / biosynthesis
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Cell Cycle Proteins
  • Immediate-Early Proteins
  • Nitric Oxide
  • Arginine
  • Nitric Oxide Synthase
  • Mitogen-Activated Protein Kinases
  • Phosphoprotein Phosphatases
  • Protein Phosphatase 1
  • Dual Specificity Phosphatase 1
  • Dusp1 protein, rat
  • Protein Tyrosine Phosphatases